Background Many psychiatric disorders including schizophrenia, bipolar disorder and major
depression convey an excess burden of cardiovascular morbidity and mortality. The …

The use of second‐generation antipsychotics (SGAs) is associated with metabolic side
effects including weight gain, diabetes mellitus and an atherogenic lipid profile. These …

OBJECTIVE: The aim of this article is to offer recommendations and rationale for gender-
specific antipsychotic treatment. METHOD: The author summarizes reviews of recent …

Background Weight gain is common for people with schizophrenia and this has serious
implications for health and well being. Objectives To determine the effects of both …

Objective: The goal of this 10-year naturalistic study was to examine, in clozapine-treated
patients, the change in cardiovascular risk factors following clozapine initiation and the …

Atypical antipsychotic drugs, by definition, differ from typical antipsychotic agents in
producing significantly fewer extrapyramidal symptoms and having a lower risk of tardive …

Objective: To characterize a model of atypical antipsychotic drug‐induced obesity and
evaluate its mechanism. Research Methods and Procedures: Chronically, olanzapine or …

Several major developments have occurred since the last edition of Handbook of Obesity:
Clinical Applications, including new clinical trials, discoveries related to drug use, and …

Changes of the tumor necrosis factor-alpha (TNF-α) system have been shown to be involved
in the development of psychiatric disorders and are additionally associated with changes in …

The prevalence of diabetes is increased in patients with schizophrenia. Although many
reasons, including hereditary and lifestyle factors, contribute to this association, recently …